HaloMD is a middleman that became the top filer of out-of-network billing disputes on behalf of medical providers.
FDA officials said an internal analysis found results were not submitted for nearly 30% of studies “highly likely” to fall under mandatory reporting requirements.
HaloMD is a middleman that became the top filer of out-of-network billing disputes on behalf of medical providers.
CMS greenlights more than 150 digital health companies for its ACCESS experiment, a new program for tech-backed chronic care with outcome-aligned payments.
President Trump vowed to take on health insurers, but his policies tell a different story.
Scientists have developed a new way to fight gum disease without wiping out the mouth’s helpful bacteria—a major shift from traditional treatments. Instead of killing everything, this targeted approach blocks only the harmful microbes that drive periodontitis, allowing beneficial bacteria to thrive and restore balance naturally.
New research reveals that obesity affects men and women in surprisingly different ways. Men are more likely to develop harmful abdominal fat and signs of liver stress, while women show higher inflammation and cholesterol levels. These differences could help explain why health risks vary between sexes. Scientists say this could lead to more tailored treatments for obesity.
Revolution Medicines 'unprecedented' cancer trial data, Allogene's off-the-shelf CAR-T, and other biotech news
Landmines ahead for Vinay Prasad’s successor, hospitals and chatbots, and more health news from Morning Rounds
Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who got chemotherapy
In a trial, metastatic pancreatic cancer patients on the medicine lived twice as long as those on chemotherapy.
The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.
The inflammatory bowel disease therapy succeeded in its first major testing, setting up a competition with several large drugmakers.
Erectile dysfunction is more than a sexual issue.
A handful of hospitals are launching their own chatbots, a risky bet aimed at better serving current patients and gaining new ones.
Who would want to be the head of the FDA's Center for Biologics Evaluation and Research?
A psychologist, she urged patients to confront the things that frightened them, revolutionizing her field’s approach to post-traumatic stress disorder.
A major study suggests that when you eat could play a key role in staying lean. People who fast longer overnight and start their day with an early breakfast were more likely to have a lower BMI years later. Scientists think this is because eating earlier aligns better with the body’s internal clock. But skipping breakfast as part of intermittent fasting didn’t offer the same advantage—and may even be tied to unhealthy habits.
“Even if not everybody is losing a ton of money right now, you're creating this culture of large numbers of gamblers,” Isaac Rose-Berman says on the First Opinion Podcast.
“Is ‘lack of education’ really what we think the problem is in prevention care?” a STAT reader asks.
Whether you’re looking to manage a health condition, lose weight or simply eat better, we want to hear from you.
The Justice Department's actions on illegal vapes pales next to the scale of the problem, anti-smoking advocates say.
A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The Trump administration this week acknowledged it made a significant error in figures it used to help justify a fraud probe into New York’s Medicaid program
CAR-T promise in autoimmunity, GSK's goodbye to leucovorin, and more biotech news
And more pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter
A revised ACIP charter, sports betting and gambling addiction, and other health news from Morning Rounds
“In my most honest of moments, what I want from the medical community is the chance to trust it again,” a MAHA advocate writes.
“What MAHA has built, in a relatively short time, is social capital,” writes Monica L. Wang.
In this week's STATus Report, host Alex Hogan dives into how sports betting apps hook users — and how he himself fell for some too-good-to-be-true promotions.
White House officials solicited messaging ideas from leaders of the Make America Healthy Again movement, which has soured on some recent administration actions.
Who needs more than two employees when artificial intelligence can do so many corporate tasks? It’s super efficient — and a little bit lonely.
Health tech companies are working to make medical records more portable, but so far, the effort is voluntary.
The charter, published on Thursday, alters the makeup and purpose of the panel, opening the door for Health Secretary Robert F. Kennedy Jr. to reclaim his revision of national vaccine policy.
Dr. Jay Bhattacharya objected to the study’s methodology, saying it gave an inaccurate picture of the vaccine’s benefits.
The panel had become a flashpoint as RFK Jr.'s health department worked to limit the number of recommended childhood shots.
This week on "The Readout LOUD": Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
Democrats are focused on health care affordability as costs keep climbing.
CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.
In this edition of Health Tech: FDA rejects a proposal to deregulate certain types of AI devices, pharma invests $50 million in DTx, and more.
Try another keyword or clear the search box.